Denali (DNLI) news

Denali Therapeutics Inc.: B. Riley raises target price to $35 from $30

Denali Therapeutics Inc. (NASDAQ: DNLI) recently announced that B. Riley Securities, Inc. has raised its price target for the company's stock to $35 from $30, while maintaining a "Buy" rating. This adjustment reflects the firm's updated assessment of the company's growth potential and market…

Royalty Pharma: Including rights to 1% royalty future net sales

Royalty Pharma, a leading entity in the biopharmaceutical royalty sector, has continued to expand its portfolio through strategic transactions that include rights to a percentage of future net sales from various therapeutic products. One such example is the company’s recent agreement with Denali…

Denali Therapeutics 2Q loss/share 68c vs. loss/share 72c y/y

Denali Therapeutics Q2 total revenue USD 3.6 million

Denali Therapeutics Inc. (Nasdaq: DNLI) reported total revenue of USD 3.6 million for the second quarter of 2026, reflecting continued operations in its pipeline of investigational therapies targeting neurodegenerative and lysosomal storage diseases. The company has not disclosed a breakdown of…

Denali Therapeutics received gross proceeds of $195.0M

Denali Therapeutics Inc. recently announced that it has raised $195.0 million in gross proceeds through a financing transaction [1]. The funds will be allocated toward advancing the company’s pipeline of therapeutic candidates, with a focus on late-stage clinical development programs. The financing…